Langley, R.; Thaci, D.; Blauvelt, A. .; Tsai, T.-F.; Miller, M. .; Yu, J.; Shen, Y.-K. .; You, Y.; Yang, Y.-W.; Papp, K. .; Puig, L.; Foley, P. Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated With Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials. J of Skin 2022, 6, s1.